BHD-associated renal cancer shares some of the clinical features of the tuberous sclerosis complex syndrome, which on its own also regulate proteins involved in the mTOR pathway, and should be part of the differential diagnosis when considering BHD. This evidence concerns the gene MTOR and Birt-Hogg-Dube syndrome.